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Background: There has been a progressive increase in the use of bioprostheses for
the management of aortic valve disease. Bioprostheses, however, undergo structural
degeneration and require replacement in the future especially when implanted in
younger age group. Such reoperations carry a high risk especially in elderly patients
with multiple comorbidities. Transcatheter aortic valve implantation (TAVI) as a valve-
in-valve (V-in-V) procedure may be a reasonable alternative.
Methods: Between February 2009 and February 2011, 31 patients underwent TAVI as
a V-in-V using the Edwards Sapien™ valve for the management of failed aortic
bioprostheses in United Kingdom. Twenty five had previous stented valves, 3 stentless,
and 3 homografts. The youngest patient was 29 years old and the oldest on 91. The
mean age was 79.77 ± 7.89 years and 16 (55%) were female. The mean logistic
Euroscore was 31.87 ± 10.81 and 92% were in New York Heart Association (NYHA)
functional class III-IV. Ten patients presented with predominant stenosis and 21 with
regurgitation. Transapical (TA) approach was preferred approach with 26 patients
undergoing implant with TA route using Ascendra system and 5 with Transfemoral
route using Retroflex or Novoflex delivery system.
Results: Procedural success was achieved in all but 2 patients (93.5%). There were
two intra-operative deaths, both due to severe intraoperative regurgitation; one due to
torn leaflet while crossing the valve retrograde with earlier version of Retroflex and
other due to valve embolisation in a stentless valve due to undersizing. Amongst the
survivors there was no 30-day mortality or stroke. There was a significant decrease in
mean gradient across the 9 previously stenotic valves from 49.0± 21.2 to 11.4 ± 5.2
mmHg (P<0.001). None of the patients had ≥ Grade 1 AR at discharge. One patient
required insertion of a permanent pacemaker for persistent AV block. Follow up was
complete and all the patients were alive and in NYHA class I-II at a median follow up
of 218 days.
Conclusion: The use of TAVI as a V-in-V for the treatment of failed bioprostheses is
safe, feasible and offers excellent early results.
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Background: Reviewing the current literature conventional aortic valve replacement
(AVR) for aortic valve stenosis or regurgitation is safe and performed with excellent
results. However, a significant number of bioprosthetic valves fail within 15years, at
a time when the patient’s risk of redo-surgery has increased. The Medtronic CoreValve
ReValving System (MCV) for transfemoral aortic valve implantation (TAVI) represents
an alternative. Therefore, the aim of the study was to elucidate whether TAVI in patients
(pts) with a failing aortic bioprosthesis is safe and feasible.
Methods: Pts with symptomatic aortic valve disease and higher surgical risk were
enrolled. MCV implantation was performed using the transfemoral approach under
local anesthesia. Clinical events were recorded and echocardiography was performed
to evaluate hemodynamics at follow-up.
Results: A total of 26pts (age 78±7years) with a logEuroSCORE of 33±17.6% were
treated so far. The duration between conventional AVR and MCV implantation was
56±44months, the inner diameter of the bioprosthesis was 21.7±2.3mm. Twenty pts
received the TAVI for treatment of a stenotic bioprosthetic valve, whereas five were
treated because of severe aortic regurgitation. The MCV prosthesis was successfully
implanted in all patients. In those with stenosis, the mean gradient declined from
46±16mmHg to 12±7mmHg after MCV (p<0.05), in those with AR the level declined
by two. Additionally the fraction of pts with NYHA class III/IV decrease from 75% to
15% and was stable through out a mean follow-up of 410±183days. There was no
intraprocedural death, one patient died from a severe stroke and one patient from
cardiac failure within 24h after TAVI. There was one further death during the one-year
follow-up period (30day-mortality:7.7%). Applying the VARC criteria device success
was achieved in 22pts (85%). Freedom from the combined safety endpoint was
detected in 20pts (79%).
Conclusion: These results suggest that TAVI into a failing aortic bioprosthetic and the
use of the MCV is feasible, safe and improves hemodynamics in high risk patients.
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Background: Transcatheter aortic valve-in-valve (VIV) implantation is an emerging
therapeutic alternative for patients with failed surgical bioprosthetic valves. This
technique might obviate the need for a redo surgical procedure. The clinical experience
with VIV implantation is still limited, and it is currently considered an off-label
treatment. We present the procedural and clinical results from a large worldwide
retrospective VIV Registry.
Methods: Data on baseline patient characteristics, procedural parameters, and outcome
up to June 2011 were collected from 35 cardiac centers that have performed VIV
procedures using a uniform case-report form.
Results: In total, 159 VIV procedures were performed (1 to 25 procedures per center,
median 3); men 50.9%; ages ranged from 25 to 91 years (mean, 77.4±10.5 years). The
prevalence of severe co-morbidities was very high: the mean calculated logistic
EuroSCORE was 30.6±17.4% and the Society of Thoracic Surgeons (STS) risk score,
12.5±11.8%. Patients had had up to 4 previous surgeries; one previous surgery in 81%
of cases. The main mode of bioprosthesis failure was stenosis (n= 75, 47.2%), followed
by regurgitation (n=64, 40.3%) and combined stenosis and regurgitation (n=20, 12.6%).
The mean aortic-valve area measured 0.98±0.55 mm2, and the valve gradients
(max/mean), 66.5±30.9/38.9±19.8 mmHg. Mean left ventricular ejection fraction was
49.6±13.2%. One-hundred and two procedures (64.2%) were performed using the
CoreValve device and 57 (35.8%) using the Edwards-SAPIEN valve. Femoral access
was used in 109 cases (68.6%), apical in 38 (23.9%), axillary in 10 (6.3%), and direct-
aortic in 2 (1.3%). Implantation was successful in 96.9% of cases, which showed a
mean decrease in valve gradients to 27.5±13.6/15.8±8.6 mmHg. Adverse outcomes
consisted of significant aortic regurgitation (≥2) in 6.9% of cases, need for pacemaker
implantation in 8.7%, and major stroke in 2.1%. The median duration of hospital stay
was 8 days. The 30-day total death rate was 8.6%, and the cardiac mortality rate was
6.1%.
Conclusion: Analysis of the retrospective global registry data indicates that the
transcatheter VIV procedure is feasible and relatively safe in very high risk patients
with failed surgical bioprosthetic valves.
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Background: Device malposition after transcatheter aortic valve replacement can
cause significant clinical and hemodynamic instability. Aortic regurgitation following
transcatheter heart valve (THV) implantation may be valvular due to prosthetic leaflet
dysfunction or paravalvular due to poor annular sealing. When regurgitation is severe
implantation of a second valve (THV-in-THV) may be effective by restoring normal
leaflet function or extending the annular seal.
Methods: Patients undergoing aortic balloon-expandable THV-in-THV implantation
at 3 centres (St. Paul’s Hospital, Vancouver, the Quebec Heart and Lung Institute,
Quebec, and the Cleveland Clinic, Cleveland) were studied.
Results: A total of 19 patients (age 80 ± 8 years, 53% male) were analyzed. Aortic
regurgitation after the first implanted valve was paravalvular in 14 patients (implant
too high in 2 patients, too low in 10 patients, and angiographically correct positioning
in 2 patients) and transvalvular in 5 patients (4 Edwards SAPIEN valves, 1 Cribier
Edwards valve). THV-in-THV implantation was successful in 17/19 (89%), while 2
patients (11%) required conversion to open heart surgery (the second valve embolized
in both cases, 1 patient died in hospital). None of the patients had transvalvular aortic
regurgitation after the second procedure. In those 17 patients who underwent a
successful THV-in-THV implantation, paravalvular aortic regurgitation was none in
4, mild in 11 and moderate to severe in 2 patients. Mean aortic valve gradient fell from
36 ± 11 mmHg to 13 ± 5 mmHg (p < 0.001) after implantation of the second valve.
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Mortality at 30 days and 1 year was 11.8% and 22.7%, respectively. At one year follow-
up, all but one patient was NYHA class 1 or 2 and the mean gradient across the aortic
valve remained stable (14 ± 5 mmHg).
Conclusion: This multicenter study shows that THV-in-THV implantation is feasible
and results in satisfactory short and mid-term outcomes.
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Background: Despite growing interest in transcatheter aortic valve implantation
(TAVI) as an alternative to surgical aortic valve replacement for select patients with
severe aortic stenosis, relatively little is known about the predictors of adverse
outcomes following TAVI.
Methods: We studied 126 consecutive patients (mean age 84±5 years; 59% women;
Euroscore: 21.3±11) with symptomatic severe aortic stenosis (aortic valve area<0.6
cm2/m2 and NYHA class≥III) who underwent TAVI at our institution between
November 2008 and May 2011 using transfemoral Edwards-Sapien© (66%),
transapical Edwards-Sapien© (23%) and transfemoral Medtronic Corevalve© (11%)
devices. The primary end-point was the occurrence of any cardiovascular death (fatal
stroke, MI, heart failure and/or sudden cardiac death). We also recorded the incidence
of major adverse cardiovascular events (MACE), that combined cardiovascular death+
stroke+ myocardial infarction+ acute heart failure.
Results: The acute procedural success rate was 98%; at 1 year, the cumulative
incidence of MACE and cardiovascular death was 31.1% and 9 %, respectively. In
multivariable analyses adjusting for clinical and echocardiographic risk factors
(including left ventricle ejection fraction), presence of a baseline transvalvular gradient
<40 mmHg was a significant predictor of 30-day MACE in the total sample (OR=4.5,
95% CI 1.6-12.4; P=0.004) as well as in patients with an ejection fraction ≥50%
(OR=12.5, 95% CI 3.4-46.2; P<0.001). In multivariable analyses, low transvalvular
gradient was also associated with increased hazards for MACE (HR=3.2, 95% CI 1.6-
6.4; P<0.001) and cardiovascular death (HR=3.9 95% CI 1.1-13.9; P=0.03) within 1
year following TAVI
Conclusion: Presence of a low transvalvular gradient (<40 mmHg) prior to TAVI was
associated with a greater risk of major adverse events, including cardiovascular death,
up to 1 year following the procedure. Pre-procedural transvalvular gradient could be
used to identify patients at a high risk for adverse outcomes following TAVI.
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Background: Access for transcatheter aortic valve implantation (TAVI) in patients
with no optional peripheral artery access still remains a serious issue, since transapical
approach is frequently associated with myocardial damage and pleural effusion.
Recently, Transaortic (TAo) approach has been developed to address these problems.
The purpose of this study was to evaluate the efficacy and safety of TAo approach in
TAVI using the Edwards Sapien valve.
Methods: Among 365 patients included in our prospective TAVI database (October
2006 to June 2011), TAo-TAVI was performed in 25 consecutive patients excluded
from femoral or subclavian access since january 2011. We evaluated the clinical
outcomes according to the VARC definitions. The access was carefully selected
according to CT-scan assessment of ascending aorta. Through an upper
ministernotomy, the aorta was prepared for cannulation and punctured. After retrograde
crossing of the aortic valve, the Ascendra sheath was inserted to deploy the valve after
predilatation.
Results: Patients were 84.9±4.2 (76-93) years old and EuroSCORE 17.1±7.9%. The
23 mm valve was used in 5 cases, 26mm in 15 and 29mm in 5. In 4 patients, complete
off pump revascularization (2-4 grafts) was achieved in the same session before TAVI.
Device success was achieved in all cases. Post-procedural aortic regurgitation ≥2/4
was observed in 1 case (4%). Transfusion ≥4units was required in 1 patient (10%) who
had annulus rupture successfully corrected. There were no access site complications,
no cases of valve migration or conversion to open-heart surgery. Intensive care unit
and total hospital stay were 3.1±2.1 and 19.0±6.8 days, respectively. Mortality and
combined safety endpoint at 30-day was noted in 0 and 10%, respectively.
Conclusion: Transaortic approach for Sapiens XT valve implantation can be performed
with a low complication rate and excellent outcome. This approach may be a promising
alternative to the conventional transapical approach.
TAVR II 
Room 132
Tuesday, November 8, 2011, 10:15 am - 12:25 pm
(Abstract nos 129 - 138)
TCT-129
Outcome of Conservative Management in Patients with Aortic Valve Stenosis
Ineligible for Transcatheter Treatment
Massimo Napodano, Ermela Yzeiraj, Valeria Gasparetto, Chiara Fraccaro,
Giuseppe Tarantini, Paolo Buja, Gianclaudio Falasco, Roberto Bianco, Gino
Gerosa, Giambattista Isabella, Sabino Iliceto
Dpt. of Cardiac Thoracic and Vascular Sciences. University of Padova, Padova,
Italy
Background: Transcatheter Aortic Valve Implantation (TAVI) favourably compared
to conservative management in inoperable patients and to surgery in high-risk patients
affected by aortic stenosis. However, the outcome of high-risk and inoperable patients
resulting ineligible for TAVI has not been yet investigated. We prospectively evaluated
clinical outcome of patients affected by aortic valve stenosis ineligible for TAVI.
Methods: All high surgical risk patients referred to our cardiovascular department for
severe aortic stenosis requiring valve replacement were included in a prospective
single-centre registry. High surgical risk was defined by the presence of: 1.age ≥ 75
with a logistic EuroSCORE ≥ 15%; or 2.age > 65 plus one or more inoperable criteria
such as porcelain aorta, previous open chest surgery, neurological dysfunction, severe
chronic obstructive pulmonary disease (FEV1 < 1L), liver cirrhosis (Child ≥B), severe
chronic kidney disease, stroke, severe connective tissue disease or hostile thorax.
Eligibility criteria for TAVI were based on clinical and anatomic characteristics
compatible with the current devices: Medtronic CoreValve III generation and Edwards
Sapien/Sapien XT transfemoral or transapical approach.
Results: Of 300 patients who were denied surgery, 225 (75%) resulted eligible for
TAVI and 75 (25%) did not. Causes of ineligibility for TAVI were frailty status (n=22),
severe mitral regurgitation (≥ 3+/4) (n=18), inadequate aortic annulus size (n=18),
severe left ventricular dysfunction (n=6), no-access (n=8) and hemorrhagic diathesis
(n=3). Of the 225 eligible for TAVI, 187 (83%) underwent TAVI with a 30-day
mortality of 4.2%; 18 (8%) died before intervention; 16 (7%) refused the procedure; 4
(2%) were excluded by referral physician and died. At 1-year, estimated survival was
89% in TAVI patients versus 49% in patients ineligible to TAVI. Indeed, cardiovascular
mortality was largely prevalent in TAVI ineligible patients, whereas non-cardiovascular
mortality was largely prevalent in TAVI patients.
Conclusion: Using current devices and approaches the most frequent causes for TAVI
ineligibility are not related to anatomical criteria but to clinical conditions. Patients
not eligible for TAVI have very high risk clinical features and very poor outcome.
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Background: SAVR is an invasive intervention, carrying a risk of perioperative
mortality and an alternative treatment option, transcatheter aortic valve implantation
(TAVI), has been developed. The clinical efficacy of TAVI was demonstrated in a
recently published randomized controlled trial (PARTNER). To date, however, there
is little information about the cost-effectiveness of TAVI relative to SAVR.
Methods: A 20 year Markov model was developed in Microsoft Excel® from the
perspective of the UK NHS. Treatment options included were TAVI and SAVR.
Treatment specific mortality and adverse event data were taken from the PARTNER
study (Cohort A) which was supplemented by UK specific life table information.
Resource use and cost data were drawn, where possible, on information from publicly
available national databases. Other parameters were taken from published literature.
Decrements were applied to age-specific EQ-5D population norms to generate Quality
Adjusted Life Years (QALYs). Alternative modelling approaches and data sources for
key parameters were included into the model. Extensive probabilistic and deterministic
sensitivity analyses were performed. Costs and benefits were discounted at an annual
rate of 3.5%
Results: The base case Incremental Cost-Effectiveness Ratio (ICER) was £30,538 per
QALY gained (95% Crl £21,322 to £39,287). At willingness to pay thresholds of
£30,000 per QALY, the probability that TAVI is cost-effective is 44%. Results were
not sensitive to changes in baseline survival curve, approach used to model the benefit
of TAVI, or procedure time, but sensitive to changes in procedure cost and resource
use.
Conclusion: TAVI may be a cost-effective alternative to conventional surgery at a
B37JACC Vol 58/20/Suppl B  |  November 7-11, 2011  |  TCT Abstracts/ORAL/TAVR II
www.JACC.TCTAbstracts2011
O
R
A
L
S
